WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Exit Postmarket & security

THE TAPE

FDA approves Cordis Selution SLR, the first sirolimus drug-eluting balloon sold in the US FDA panel takes up GRAIL's Galleri cancer screening PMA on September 23 FDA folds the human factors guidance into eSTAR 7.1 and widens PreSTAR to five more meeting types AVAVA raises $45M with a third of it in debt from its lead investor UpFront Diagnostics wins a CE mark for a 10-minute stroke blood test Ambu pays $45M upfront for TIMS Medical and about 7,000 US hospital installs Citi downgrades Boston Scientific over the cyberattack recovery Autonomix puts Medtronic's former chief regulatory counsel on its board FDA calls the NOxBOXi oxygen leak fix a Class II correction, three years after a Class I recall FDA approves Cordis Selution SLR, the first sirolimus drug-eluting balloon sold in the US FDA panel takes up GRAIL's Galleri cancer screening PMA on September 23 FDA folds the human factors guidance into eSTAR 7.1 and widens PreSTAR to five more meeting types AVAVA raises $45M with a third of it in debt from its lead investor UpFront Diagnostics wins a CE mark for a 10-minute stroke blood test Ambu pays $45M upfront for TIMS Medical and about 7,000 US hospital installs Citi downgrades Boston Scientific over the cyberattack recovery Autonomix puts Medtronic's former chief regulatory counsel on its board FDA calls the NOxBOXi oxygen leak fix a Class II correction, three years after a Class I recall

Financing

AVAVA raises $45M with a third of it in debt from its lead investor

MedDevice Startups Staff · 6 days ago · 2 min read · Via AVAVA announcement

AVAVA said on September 17 it raised $45 million. The package splits into $30 million of equity and a $15 million debt facility, both from Catalio Capital Management, with new and existing investors joining the equity. UBS Investment Bank and Oak Hills Securities advised.

The Boston company sells the MIRIA Skin Treatment System, an energy-based aesthetic platform built on its Focal Point Technology and cleared through 510(k). CEO Clint Carnell said the money goes to commercial scale-up, the innovation pipeline and global growth. AVAVA shipped a software upgrade it calls AVAVA 2.0 earlier this year.

One firm writing both the equity check and the debt facility keeps the cap table short and the covenants in one place. It also puts a single investor on both sides of the table if the commercial ramp slips.

Questions & Answers

How much did AVAVA raise in September 2026?

AVAVA announced a $45 million financing on September 17, 2026. It breaks into $30 million of equity and a $15 million debt facility.

Who led the AVAVA financing?

Catalio Capital Management led the equity round and also provided the $15 million debt facility. New and existing investors joined, and UBS Investment Bank and Oak Hills Securities advised AVAVA.

What does AVAVA make?

AVAVA, based in Boston, sells the MIRIA Skin Treatment System, an energy-based aesthetic platform built on its Focal Point Technology. The company says the financing funds commercial expansion and its clinical and regulatory programs.

← Back to Fundraising